Abstract Coronavirus disease 2019 (COVID-19) has emerged as a pandemic at the end of
2019 and continues to exert an unfavorable worldwide health impact on a large proportion …

The coagulopathy caused by SARS-CoV-2 seen in patients hospitalised with COVID-19,
especially those with severe or critical illness, is by now well established. Early reports in …

Background Venous thromboembolism is a major complication of coronavirus disease 2019
(COVID-19). We hypothesized that a weight-adjusted intermediate dose of anticoagulation …

vaccine effectiveness in terms of protection against actual infection; instead, effectiveness
was inferred from immunogenicity. Cellular immunity was only studied in 60% of the …

Heparin thromboprophylaxis is routinely administered during hospitalization for COVID-19.
Because of the immune stimulation related to COVID-19, there is ongoing concern regarding …

The novel coronavirus disease (COVID-19) is associated with a high incidence of
coagulopathy and venous thromboembolism that may contribute to the worsening of the …

Objective To assess the benefits and harms of different types and doses of anticoagulant
drugs for the prevention of venous thromboembolism in patients who are acutely ill and …

Αbstract Remdesivir (GS-5734), a drug initially developed to treat hepatitis C and Ebola
virus disease, was the first approved treatment for severe coronavirus disease 2019 (COVID …

Coronavirus disease 2019 (COVID-19) has been shown to be strongly associated with
increased risk for venous thromboembolism events (VTE) mainly in the inpatient but also in …

Venous thromboembolism (VTE) in patients with COVID-19 in intensive care units (ICU) is
frequent, but risk factors (RF) remain unidentified. In this meta-analysis (CRD42020188764) …